Initial characteristics of the 172 patients with primary myelofibrosis
Characteristic . | Value . |
---|---|
Patients, no. | 172 |
Age, y, median ± SD | 65 ± 9.69 |
Hemoglobin, g/L, median ± SD | 104 ± 24.5 |
White blood cell count, ×109/L, median ± SD | 11.25 ± 14.26 |
Platelet count, ×109/L, median ± SD | 297 ± 276 |
Abnormal cytogenetics* (%) | 30 of 89 (34) |
Weight loss, n (%) | 33 (19) |
Hepatomegaly, n (%) | 76 (44) |
Male/female (ratio) | 90/82 (1.1:1) |
Circulating blasts > 1%, n (%) | 60 (36) |
Immature granulocytes > 5%, n (%) | 109 (64) |
Treatment regimen, n (%) | |
Chemotherapy | 84 (49) |
Androgens | 33 (19) |
Splenectomy | 28 (16) |
Lille score, n (%) | |
Low | 78 (45) |
Intermediate | 77 (45) |
High | 17 (10) |
IWGMRT score,* n (%) | |
Low | 18 (11) |
Intermediate-low | 51 (31) |
Intermediate-high | 56 (34) |
High | 39 (24) |
Characteristic . | Value . |
---|---|
Patients, no. | 172 |
Age, y, median ± SD | 65 ± 9.69 |
Hemoglobin, g/L, median ± SD | 104 ± 24.5 |
White blood cell count, ×109/L, median ± SD | 11.25 ± 14.26 |
Platelet count, ×109/L, median ± SD | 297 ± 276 |
Abnormal cytogenetics* (%) | 30 of 89 (34) |
Weight loss, n (%) | 33 (19) |
Hepatomegaly, n (%) | 76 (44) |
Male/female (ratio) | 90/82 (1.1:1) |
Circulating blasts > 1%, n (%) | 60 (36) |
Immature granulocytes > 5%, n (%) | 109 (64) |
Treatment regimen, n (%) | |
Chemotherapy | 84 (49) |
Androgens | 33 (19) |
Splenectomy | 28 (16) |
Lille score, n (%) | |
Low | 78 (45) |
Intermediate | 77 (45) |
High | 17 (10) |
IWGMRT score,* n (%) | |
Low | 18 (11) |
Intermediate-low | 51 (31) |
Intermediate-high | 56 (34) |
High | 39 (24) |
SD indicates standard deviation.
Data were not available for all patients.